203 related articles for article (PubMed ID: 15114431)
21. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.
Elens L; Nieuweboer AJ; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; van Gelder T; Mathijssen RH; van Schaik RH
Pharmacogenet Genomics; 2013 Mar; 23(3):148-55. PubMed ID: 23324807
[TBL] [Abstract][Full Text] [Related]
22. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.
Yu KS; Cho JY; Jang IJ; Hong KS; Chung JY; Kim JR; Lim HS; Oh DS; Yi SY; Liu KH; Shin JG; Shin SG
Clin Pharmacol Ther; 2004 Aug; 76(2):104-12. PubMed ID: 15289787
[TBL] [Abstract][Full Text] [Related]
23. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
24. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.
Oneda B; Crettol S; Jaquenoud Sirot E; Bochud M; Ansermot N; Eap CB
Pharmacogenet Genomics; 2009 Nov; 19(11):877-83. PubMed ID: 19801957
[TBL] [Abstract][Full Text] [Related]
25. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo.
Miao J; Jin Y; Marunde RL; Gorski CJ; Kim S; Quinney S; Radovich M; Li L; Hall SD
Pharmacogenomics J; 2009 Oct; 9(5):319-26. PubMed ID: 19506580
[TBL] [Abstract][Full Text] [Related]
26. Effect of quercetin on CYP3A activity in Chinese healthy participants.
Duan KM; Wang SY; Ouyang W; Mao YM; Yang LJ
J Clin Pharmacol; 2012 Jun; 52(6):940-6. PubMed ID: 21680781
[TBL] [Abstract][Full Text] [Related]
27. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels.
Katz DA; Grimm DR; Cassar SC; Gentile MC; Ye X; Rieser MJ; Gordon EF; Polzin JE; Gustavson LE; Driscoll RM; O'dea RF; Williams LA; Bukofzer S
Clin Pharmacol Ther; 2004 Jun; 75(6):516-28. PubMed ID: 15179406
[TBL] [Abstract][Full Text] [Related]
28. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
Wong M; Balleine RL; Collins M; Liddle C; Clarke CL; Gurney H
Clin Pharmacol Ther; 2004 Jun; 75(6):529-38. PubMed ID: 15179407
[TBL] [Abstract][Full Text] [Related]
29. Effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men.
Brennan BJ; Brown AB; Kolis SJ; Rutman O; Gooden C; Davies BE
J Clin Pharmacol; 2006 Feb; 46(2):222-8. PubMed ID: 16432274
[TBL] [Abstract][Full Text] [Related]
30. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
Wang YH; Jones DR; Hall SD
Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501
[TBL] [Abstract][Full Text] [Related]
31. CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene.
Eap CB; Fellay J; Buclin T; Bleiber G; Golay KP; Brocard M; Baumann P; Telenti A
Pharmacogenetics; 2004 Apr; 14(4):255-60. PubMed ID: 15083070
[TBL] [Abstract][Full Text] [Related]
32. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
Elens L; Nieuweboer A; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; Mathijssen RH; van Schaik RH
Pharmacogenomics; 2013 Jan; 14(2):137-49. PubMed ID: 23327575
[TBL] [Abstract][Full Text] [Related]
33. Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem.
Yamamoto T; Kubota T; Ozeki T; Sawada M; Yokota S; Yamada Y; Kumagai Y; Iga T
Clin Chim Acta; 2005 Dec; 362(1-2):147-54. PubMed ID: 16024008
[TBL] [Abstract][Full Text] [Related]
34. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers.
Fukuda T; Onishi S; Fukuen S; Ikenaga Y; Ohno M; Hoshino K; Matsumoto K; Maihara A; Momiyama K; Ito T; Fujio Y; Azuma J
Pharmacogenomics J; 2004; 4(1):34-9. PubMed ID: 14647405
[TBL] [Abstract][Full Text] [Related]
35. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
[TBL] [Abstract][Full Text] [Related]
36. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men.
Yang G; Fu Z; Chen X; Yuan H; Yang H; Huang Y; Ouyang D; Tan Z; Tan H; Huang Z; Zhou H
Clin Ther; 2011 Dec; 33(12):2060-70. PubMed ID: 22177374
[TBL] [Abstract][Full Text] [Related]
37. Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries.
van Dyk M; Marshall JC; Sorich MJ; Wood LS; Rowland A
Eur J Clin Pharmacol; 2018 Jul; 74(7):913-920. PubMed ID: 29572563
[TBL] [Abstract][Full Text] [Related]
38. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo.
Lowry JA; Kearns GL; Abdel-Rahman SM; Nafziger AN; Khan IS; Kashuba AD; Schuetz EG; Bertino JS; van den Anker JN; Leeder JS
Clin Pharmacol Ther; 2003 Mar; 73(3):209-22. PubMed ID: 12621386
[TBL] [Abstract][Full Text] [Related]
39. Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation.
Fromm MF; Schwilden H; Bachmakov I; König J; Bremer F; Schüttler J
Eur J Clin Pharmacol; 2007 Dec; 63(12):1129-33. PubMed ID: 17786417
[TBL] [Abstract][Full Text] [Related]
40. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.
Roy JN; Barama A; Poirier C; Vinet B; Roger M
Pharmacogenet Genomics; 2006 Sep; 16(9):659-65. PubMed ID: 16906020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]